Markets:

Overview

News

Currencies

International

Treasuries

Neuronetics, Inc. - Common Stock (NQ:STIM)

1.410 -0.030 (-2.08%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Butterfly Network And 3 Other Stocks Under $2 Executives Are Aggressively Buying ↗

September 03, 2024

Via Benzinga

NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University

August 20, 2024

Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility

From Neuronetics

Via GlobeNewswire

Gold Gains Over 1%; Starbucks Shares Move Higher ↗

August 12, 2024

Via Benzinga

Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations ↗

August 12, 2024

Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expects mid-teens growth in 2025 and 2026, with $15M in cost savings and...

Via Benzinga

Crude Oil Surges 2%; B. Riley Financial Shares Plunge ↗

August 12, 2024

Via Benzinga

STIM Stock Earnings: Neuronetics Misses EPS, Misses Revenue for Q2 2024 ↗

August 12, 2024

STIM stock results show that Neuronetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Dow Dips 150 Points; Monday.com Posts Upbeat Earnings ↗

August 12, 2024

Via Benzinga

Topics Stocks

NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month

August 01, 2024

New initiative aims to provide information and resources for teen mental health amidst rising public health concerns

From Neuronetics

Via GlobeNewswire

Aetna Policy Update Expands TMS Availability for Adolescents With Depression

July 22, 2024

Coverage criteria consistent with recent FDA clearance for NeuroStar TMS

From Neuronetics

Via GlobeNewswire

3 Neurotech Stocks Bridging Mind and Machine ↗

July 18, 2024

These neurotech stocks stand at the cutting edge of healthcare, but early entrants in new fields tend to be long-term winners.

Via InvestorPlace

California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults

July 11, 2024

NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal

From Neuronetics

Via GlobeNewswire

BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents

July 10, 2024

Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health

From Neuronetics

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

July 10, 2024

Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news worth reading this morning!

Via InvestorPlace

NeuroStar® Launches Better Me Provider Program Nationwide

July 01, 2024

The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry

From Neuronetics

Via GlobeNewswire

NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

June 13, 2024

Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024

From Neuronetics

Via GlobeNewswire

Neuronetics And 3 Other Stocks Under $3 Insiders Are Buying ↗

June 07, 2024

Via Benzinga

Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents

May 15, 2024

Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older

From Neuronetics

Via GlobeNewswire

Nasdaq Moves Lower; Great Lakes Dredge & Dock Shares Surge Following Upbeat Earnings ↗

May 07, 2024

Via Benzinga

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 07, 2024

Via Benzinga

Crude Oil Edges Lower; UBS Shares Jump After Q1 Earnings ↗

May 07, 2024

Via Benzinga

STIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

STIM stock results show that Neuronetics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month

May 01, 2024

The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance

From Neuronetics

Via GlobeNewswire

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

April 10, 2024

Lack of early symptom improvement is not predictive of final responder status

From Neuronetics

Via GlobeNewswire

Top 5 Health Care Stocks That May Plunge In March ↗

March 28, 2024

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 25, 2024

Via Benzinga

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

March 25, 2024

NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older

From Neuronetics

Via GlobeNewswire

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 25, 2024

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Via Benzinga

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

March 07, 2024

From Neuronetics

Via GlobeNewswire

Earnings Scheduled For March 5, 2024 ↗

March 05, 2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.